Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(3.16) by 33.54 percent. This is a 65 percent increase over losses of $(6.00) per share from the same period last year.
DA Davidson Downgrades Telos to Neutral
DA Davidson analyst Rudy Kessinger downgrades Telos (NASDAQ:TLS) from Buy to Neutral.